1. Home
  2. SVV vs TSHA Comparison

SVV vs TSHA Comparison

Compare SVV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

SELL

Current Price

$9.28

Market Cap

1.4B

ML Signal

SELL

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

SELL

Current Price

$3.64

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SVV
TSHA
Founded
1954
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SVV
TSHA
Price
$9.28
$3.64
Analyst Decision
Buy
Strong Buy
Analyst Count
12
13
Target Price
★ $14.23
$13.00
AVG Volume (30 Days)
1.3M
★ 3.5M
Earning Date
10-29-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 5.56
EPS
★ 0.10
N/A
Revenue
★ $1,678,954,000.00
$9,773,000.00
Revenue This Year
$6.18
N/A
Revenue Next Year
$7.96
$1,023.00
P/E Ratio
$92.80
★ N/A
Revenue Growth
9.19
★ 17.28
52 Week Low
$6.91
$3.69
52 Week High
$13.88
$7.30

Technical Indicators

Market Signals
Indicator
SVV
TSHA
Relative Strength Index (RSI) 43.23 19.82
Support Level $8.80 N/A
Resistance Level $9.59 $6.68
Average True Range (ATR) 0.28 0.27
MACD 0.05 -0.06
Stochastic Oscillator 57.24 8.07

Price Performance

Historical Comparison
SVV
TSHA

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: